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ABSTRACT
The recent growth in the number of publicly avail-
able cancer omics databases has been accompanied
by the development of various tools that allow re-
searchers to visually explore these data. In 2015, we
built MEXPRESS, an online tool for the integration
and visualization of gene expression, DNA methyla-
tion and clinical data from The Cancer Genome Atlas
(TCGA), a large collection of publicly available multi-
omics cancer data. MEXPRESS addresses the need
for an easy-to-use, interactive application that allows
researchers to identify dysregulated genes and their
clinical relevance in cancer. Furthermore, while other
tools typically do not support integrated visualization
of expression and DNA methylation data in combina-
tion with the precise genomic location of the methy-
lation, MEXPRESS is unique in how it depicts these
diverse data types together. Motivated by the large
number of users MEXPRESS has managed to attract
over the past 3 years and the recent migration of
all TCGA data to a new data portal, we developed
a new version of MEXPRESS (https://mexpress.be).
It contains the latest TCGA data, additional types of
omics and clinical data and extra functionality, allow-
ing users to explore mechanisms of gene dysregula-
tion beyond expression and DNA methylation.
INTRODUCTION
Publicly available cancer multi-omics databases are a valu-
able asset for scientific research. They help researchers and
clinicians decipher the genomic drivers of tumorigenesis,
they serve as a valuable resource for the discovery of novel
biomarkers and they can be used as independent valida-
tion cohorts. One example of such a database is The Can-
cer Genome Atlas (TCGA). This project, a collaboration
between the National Cancer Institute (NCI) and the Na-
tional Human Genome Research Institute, offers multi-
dimensional data on 33 different types of cancer. Analy-
sis of these data has already led to several compelling new
insights, such as the discovery of tissue-independent onco-
genic molecular signatures and therapeutically actionable
alterations (1,2).
User-friendly tools to analyze and visualize large-scale
cancer multi-omics data are essential to unlock the full po-
tential of these datasets, as they enable researchers and clin-
icians without a computational background to explore the
data by themselves. The Xena browser (https://xenabrowser.
net/), cBioPortal (http://www.cbioportal.org/) (3) and Wan-
derer (http://maplab.imppc.org/wanderer/) (4) are examples
of web-based tools that allow researchers to integrate, ana-
lyze and visualize different types of cancer omics data.
In 2015, we created and published MEXPRESS, an on-
line tool for the visualization of TCGA gene expression,
DNA methylation and clinical data, as well as the rela-
tionships between them (5). One of our goals was to make
MEXPRESS as simple to use as possible. Only three steps
are required to create a figure: entering a gene, selecting a
cancer type and clicking a button. Another major incentive
was the lack of proper support for DNA methylation data
in existing tools.
DNA methylation consists of the covalent, and therefore
reversible, binding of a methyl group to cytosine, one of the
four building blocks of DNA. In humans, DNA methyla-
tion is almost exclusively restricted to the cytosines of CpG
dinucleotides (a cytosine, C, followed by guanine, G). It
plays a critical role in the regulation of gene expression, and
abnormal DNA methylation patterns are found in virtually
every type of human cancer (6). The precise genomic loca-
tion of DNA methylation is one of the most important fac-
tors in the regulatory effect of DNA methylation on gene
expression (7), and this is where MEXPRESS distinguishes
itself from other available tools.
Using MEXPRESS, researchers can easily investigate the
available TCGA DNA methylation data at individual CpGs
in relation to their precise genomic location, while at the
same time exploring the correlation of the DNA methyla-
tion data with gene expression and multiple clinical vari-
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Figure 1. MEXPRESS visualization of the TCGA data for GSTP1 in prostate adenocarcinoma. (A) The default view, in which the samples are sorted
by their GSTP1 expression levels and the samples without expression data were removed. The figure and the statistics on the right hand side show how
GSTP1 expression and promoter DNA methylation are negatively correlated. (B) The summary view, a novel feature of MEXPRESS, in which the samples
have been divided into two groups based on their GSTP1 expression level. The horizontal lines at each probe location indicate the median percentage of
methylation ( value), whereas the vertical lines mark the range between the 25th and the 75th percentile.
ables. Figure 1A shows the well-known inhibitory effect of
promoter hypermethylation on the expression of GSTP1 in
prostate cancer (8). The visual interpretation of the data
(less GSTP1 expression in samples with more promoter
methylation) is confirmed by the statistical analysis of the
correlation between DNA methylation and gene expression
(Pearson correlation coefficients ranging from −0.664 to
−0.803 for promoter region probes). We chose to recreate
Figure 1 of the original publication (5) to highlight both
the similarities (overall layout) and some of the differences
(design, ability to zoom in) between the old and the new
version of MEXPRESS.
Updates
Several events encouraged us to build a new version of
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tracted a sizeable number of users and we still receive pos-
itive feedback more than 3 years after the initial publi-
cation (5). Between August 2015 and January 2019, a to-
tal of 19 623 users visited MEXPRESS and we counted
36 503 sessions for an average of more than 28 sessions
per day. Second, the original MEXPRESS back-end pulled
data from the TCGA data portal (https://tcga-data.nci.
nih.gov/). However, this portal is no longer online and all
TCGA data have been migrated to the NCI’s Genomic Data
Commons (GDC) data portal (https://portal.gdc.cancer.
gov/), meaning that any updates to the TCGA data were
no longer incorporated in the MEXPRESS database.
To address the TCGA data migration, we decided to pull
the latest GDC TCGA data from the Xena public data hubs
(http://xena.ucsc.edu/public-hubs/). We opted for Xena in-
stead of directly querying GDC because Xena offers much
more straightforward data access and pre-merged datasets,
meaning that in order to get, for example, all colon adeno-
carcinoma DNA methylation data only one file needs to be
downloaded. The GDC portal on the other hand provides
these data as separate files for each sample. Another advan-
tage of using the Xena data hubs is that all data have been
processed using the latest human genome assembly (hg38).
While the basic functionality remains the same (enter a
gene name and select a cancer type to generate a figure), the
new version of MEXPRESS contains multiple incremental
improvements, resulting in a substantial update. These up-
dates were inspired by the user feedback we have collected
since the initial publication of MEXPRESS, and by a series
of in-depth user interviews. Our goal was to improve the ex-
isting user interface and user experience and to extend the
tool’s functionality without sacrificing its user friendliness.
Besides a visual overhaul and an update to version hg38 of
the human genome, we added the following functionality
and data types:
• The ability to filter samples
Users can filter the samples in the figure by expression,
copy number or any of the clinical variables (e.g. select
only the samples from male patients where the expression
is greater than the median expression value).
• New data types
We added the following data types to the new version of
MEXPRESS: copy number variation, somatic mutations,
micro RNA (miRNA) expression, survival data, addi-
tional clinical variables and the genomic location of in-
dividual CpG dinucleotides. We also included a detailed
description of each data type.
• Extra statistical analyses
We added ANOVA to allow for the comparison of a nu-
merical variable between more than two groups (e.g. to
test if there is a difference in expression between the four
main tumor stages) and the chi-squared test, to compare
a categorical variable between groups (e.g. to test if there
is a difference in the gender distribution between normal
and tumor samples).
• Summary plot
Besides the default visualization, users also have the op-
tion to create a summary figure, which shows the sum-
marized DNA methylation data for the genomic region
selected in the default view (Figure 1B). The samples are
split into two or more groups based on the variable by
which samples were sorted by (e.g. for a numerical vari-
able, such as expression or patient age, MEXPRESS will
create two groups based on the median value of the vari-
able, whereas for a categorical variable, such as sample
type, the groups are simply defined by the different cat-
egories of this variable). For each Infinium microarray
probe visible in the figure, the DNA methylation values
are compared between the different sample groups.
• Additional visualization options
Users can choose which clinical variables they would like
to see in the figure and they can zoom in on a specific
region of the gene they plotted.
• Download options
Downloading the figures as SVG or PNG files was al-
ready possible in the original version of MEXPRESS, but
users can now also download the data that were used to
create a figure, as well as the results of the statistical anal-
yses.
• The toolbar
We collected most functionality and interactivity in a
‘toolbar’ above the figure. From this toolbar, users can
sort and filter samples, select clinical variables, show/hide
somatic mutations, switch between the default and sum-
marized view, zoom out, reset the figure, download fig-
ures and data, and find detailed information about each
data type.
• Step-by-step example
To guide our users through the new functionality, we
added a fully automated step-by-step example analysis to
the MEXPRESS homepage.
Copy number variation is one of the data types that have
been added to the new version of MEXPRESS. By integrat-
ing DNA methylation and copy number data, users can now
assess whether a difference in methylation among partic-
ular groups represents an actual difference in methylation
level or if it merely reflects an underlying difference in copy
number. Figure 2 shows a MEXPRESS visualisation of the
gene CDKN2A, a well-known tumor suppressor (9). With-
out looking at the copy number data, there appears to be
relatively strong positive correlation between CDKN2A ex-
pression and DNA methylation in the gene body. However,
by including the copy number data, we can see how many of
the samples with lower levels of CDKN2A expression also
feature homozygous deletions, which interfere with the esti-
mation of DNA methylation levels. The correlation between
DNA methylation and gene expression might therefore be
attributed to differences in copy numbers. Users could not
have arrived at this insight with the previous version of
MEXPRESS, as it lacked the copy number data.
Implementation and data sources
MEXPRESS runs on an Apache server and uses PHP to in-
teract with the back-end MySQL database. Custom python
scripts pull the following TCGA data from the Xena pub-
lic data hubs and upload these data to the MEXPRESS
database: gene expression (RNA-seq – HTSeq – FPKM-
UQ), DNA methylation (Infinium HumanMethylation450
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Figure 2. MEXPRESS visualization of the TCGA data for CDKN2A in lung squamous cell carcinoma. This figure shows the complex interplay between
gene expression, copy number, DNA methylation and somatic mutations, highlighting the value of the data types that have been added in the new version
of MEXPRESS.
TIC2 (10) thresholded), miRNA expression (miRNA-seq
RPM), somatic mutations (MuTect2 variant aggregation
and masking), phenotype and survival. The copy number
data were downloaded from the original TCGA hub (https:
//tcga.xenahubs.net), while the other data types are down-
loaded from the GDC hub (https://gdc.xenahubs.net). The
reason we used the original TCGA hub for the copy number
data is that it provides easy to interpret GISTIC2 thresh-
olded estimated values, representing homozygous deletion
(−2), single copy deletion (−1), diploid normal copy (0),
low-level copy number amplification (+1) and high-level
copy number amplification (+2).
Gene, transcript and exon coordinates were obtained
from Ensembl BioMart (https://www.ensembl.org/biomart,
Ensembl Genes 94, GRCh38.p12), while miRNA, snoRNA
and CpG island coordinates (GRCh38) were obtained from
the UCSC genome browser (11). For the Infinium mi-
croarray probes, we used the hg38 coordinates from Zhou
et al. (http://zwdzwd.github.io/InfiniumAnnotation) (12).
The breast cancer PAM50 annotation was derived from
TCGA’s own publication on human breast tumors (13). Fi-
nally, the coordinates of the individual CpG dinucleotides
are not stored in the MEXPRESS database, but are dy-
namically requested from the Ensembl REST API (http:
//rest.ensembl.org/documentation/info/sequence region).
We performed some minor processing on the TCGA data
downloaded from Xena, mostly to ensure consistency in the
sample names (all data processing was implemented in R
version 3.5.2). We also simplified some of the clinical vari-
ables, e.g. we created a new variable ‘tumor stage simplified’
in which we reduced the many pathologic stages to the four
main ones (stages one, two, three and four).
For the MEXPRESS front-end, we used Javascript,
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(version 1.2.10, https://github.com/devbridge/jQuery-
Autocomplete) and the d3.js Javascript library (ver-
sion 5.5.0, http://d3js.org/). When a user downloads a
figure, the SVG image is converted into a PNG image
using Inkscape, an open source vector graphics editor
(http://www.inksca-pe.org/).
All MEXPRESS code (back-end, front-end and data pro-
cessing) can be cloned or downloaded from this GitHub
repository: https://github.com/akoch8/mexpress.
CONCLUSION
The number of users proves that MEXPRESS, through its
ease of use and unique, integrative data overview, found its
place in the toolbox of many researchers. By combining a
comprehensive visualization and statistical analysis in a sin-
gle figure, MEXPRESS helps researchers quickly identify
dysregulations and their clinical relevance in cancer. With
this major, feedback-driven update, we aim to consolidate
MEXPRESS’s place in the set of open source web tools
available to researchers and clinicians.
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